AstraZeneca has signed a $6.9 billion deal with Daiichi Sankyo for a single antibody-drug conjugate (ADC), trastuzumab deruxtecan.
Genomics will change what patients expect from their provider, as well as change how physicians treat them. Before this happens, education on both sides is needed. This month we look at some of the big talking points.
Out of a whole host of engaging and enjoyable moments at Front Line Genomics’ recent Data Driven Drug Development (D4) conference, held in Boston on 20-21 March, one of the most memorable was definitely the triumph of nQ Medical in our innovation showcase, beating out three other contenders for the claim to be “most innovative” of the technologies on display.
Pharma giant Biogen and its Japanese partner Eisai have made the decision to halt two phase 3 trials of aducanumab, a drug created to slow Alzheimer’s by targeting brain-destroying beta-amyloid fragments. An independent monitoring committee decided that the drug was unlikely to benefit patients compared with a placebo.
Scientists from the University of California have announced a possible alternative option to electronic eye implants for those who have lost their sight: gene therapy. Virus-delivered genes for green opsin gave blind mice sight enough to determine patterns on an iPad, they found, with the therapy possibly ready for clinical trials in three years’ time.
Oxford Nanopore has made its Flongle starter packs available to purchase, following an early-access testing programme. The Flongle machine allows for smaller, on-demand DNA sequence testing at low cost.
Commercial DNA-analysing company 23andMe is looking to launch a new DNA assessment to help individuals discover their risk of developing type 2 diabetes. Several million customers will receive the information over the coming weeks.
A second individual has experienced sustained remission from HIV after their treatment ended, scientists from the University of Central London and Imperial College have found.
Scientists have used synthetic nucleotides to double the traditional number of life’s building blocks to eight.
A combination of immunotherapy drug avelumab and targeted agent axitinib has been seen to increases progression-free survival in patients with metastatic kidney cancer, scientists from the Dana-Farber Institute have reported following a phase 3 clinical trial.
TEXLab, a mathematical AI software created by scientists at Imperial College London and the University of Melbourne can predict survival rates of patients with ovarian cancer more accurately than any current method, a trial published in Nature Communications has found.
More errors occur in DNA replication during times of stress when resources are scares, scientists at the University of Toronto have found.
For the first time, scientists have changed human stem cells into functional insulin-producing cells in mice, potentially promising a breakthrough in treatment for those suffering from type 1 diabetes.